Glenmark Pharmaceuticals logo

Glenmark Pharmaceuticals financials and balance sheet

NSE: GLENMARKBSE: 532296Pharmaceuticals & BiotechnologyMid Cap

Last close ₹2,166.60down ₹31.90 (1.45%)BSE ₹2,129.60

Share price at the NSE close on 23 Oct 2026. Previous close ₹2,198.50.

52-week range of traded prices to 23 Oct 2026
₹1,792.60Low, 28 Oct 2025₹2,537.60High, 28 Aug 2026
Market cap
₹61,147 Cr176th largest listed
P/E
34.0
P/E without one-offs
16.3
P/B
5.8
Dividend yield
0.12%
ROE
18.6%
ROE without one-offs
38.6%
ROCE
39.8%
Debt to equity
0.00
Volume, NSE
8,92,79752.3% delivered

10 years at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Glenmark Pharmaceuticals annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
A loss in 1 of the 10 years shown

Operating and net margin, per cent

  • Operating margin
  • Net margin

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 4.6% of operating profit in the first full year.

The years either side of a change of basis do not compare. From the year to Mar 2024, the company's revenue for that year, ₹11,813 Cr, differs from its quarters added, ₹12,179 Cr; the company reports a discontinued business.

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue16,983
  2. Materials and goods−4,747
  3. Employee costs−3,578
  4. Other expenses−4,085
  5. Operating profit4,572
  6. Depreciation−573
  7. Other income+461
  8. One-off items−2,266
  9. Finance costs−209
  10. Profit before tax1,985
  11. Tax−623
  12. Net profit1,362

What the company owns

  • Plant, investments and other assets₹10,337 Cr
  • Receivables₹4,963 Cr
  • Inventory₹3,431 Cr
  • Cash and bank₹1,176 Cr

What pays for it: net worth and liabilities

  • Net worth₹10,512 Cr
  • Other liabilities₹5,652 Cr
  • Owed to suppliers₹3,744 Cr

Profit and loss

Consolidated, ₹ crore, years to March.Glenmark Pharmaceuticals quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 30 MayMar 2020Filed 27 JunMar 2021Filed 31 MayMar 2022Filed 30 MayMar 2023Filed 22 MayMar 2024Filed 25 MayMar 2025Filed 12 JunMar 2026Filed 29 May
Revenue from operations9,1869,1039,86510,64110,94412,30512,99011,81313,32216,983
7,1497,4888,2808,9438,8609,98510,71210,61810,97012,410
Materials and goods bought2,6143,0393,3623,6993,6994,3854,5374,4134,3534,747
Employee costs1,6411,8722,0562,2552,3442,4472,7812,8683,0223,578
Other expenses2,8942,5772,8612,9892,8173,1523,3943,3363,5954,085
Operating profit before depreciation2,0371,6151,5861,6982,0842,3202,2781,1952,3514,572
Operating margin22.2%17.7%16.1%16.0%19.0%18.9%17.5%10.1%17.7%26.9%
Materials, % of revenue28.5%33.4%34.1%34.8%33.8%35.6%34.9%37.4%32.7%28.0%
Employee costs, % of revenue17.9%20.6%20.8%21.2%21.4%19.9%21.4%24.3%22.7%21.1%
Other expenses, % of revenue31.5%28.3%29.0%28.1%25.7%25.6%26.1%28.2%27.0%24.1%
Depreciation and amortisation264302326417444487611582486573
Operating profit after depreciation1,7721,3131,2601,2811,6411,8341,6676131,8653,999
Other income379120816050167317840114461
Finance costs237286335377353298350516207209
Profit before one-off items and tax1,5721,1191,1331,0631,3381,7021,6349371,7724,251
One-off items−8101673345−261−766−901−373−2,266
Profit before tax1,4911,1191,3011,0961,3821,441868361,3991,985
3833153763204124484911,867352623
Profit from discontinued businesses–––––––397––
1,109804925776970994377−1,4341,0471,362
Other comprehensive income––−415−2468777154−6664414
Total comprehensive income––5105301,0571,070531−1,4991,1111,776
Net margin12.1%8.8%9.4%7.3%8.9%8.1%2.9%–7.9%8.0%
Belonging to the company's shareholders is left blank for the year to Mar 2023: the filing's earnings per share does not match the profit it states, and cannot be multiplied back into the owners' profit because the share it leaves the other owners is more than 10 points from the share the company's other periods state. Net margin is left blank for the year to Mar 2024: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2019Filed 30 MayMar 2020Filed 27 JunMar 2021Filed 31 MayMar 2022Filed 30 MayMar 2023Filed 22 MayMar 2024Filed 25 MayMar 2025Filed 12 JunMar 2026Filed 29 May
5,6056,0707,0649,4389,8397,8488,84910,512
5,6056,0717,0659,0879,4747,8488,84910,512
Share capital2828282828282828
Reserves5,5776,0427,0369,0589,4467,8208,82110,484
Belonging to outside owners of subsidiaries000351365000
3,8774,4864,4023,6704,3489912,1940
4,0214,1264,2014,6895,0465,8195,9676,376
3,6634,4894,3382,9564,4876921,2333,020
Total assets13,28914,68515,60417,08319,37214,35916,05019,908
6,5927,8818,2448,8019,4986,9316,7548,608
6,6976,8047,3608,2829,8747,4289,29511,300
Net debt2,9393,3743,2632,2592,878−669489−1,176
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2021Filed 31 MayMar 2022Filed 30 MayMar 2023Filed 22 MayMar 2024Filed 25 MayMar 2025Filed 12 JunMar 2026Filed 29 May
1,1311,109625−265−8283,445
1,6411,6671,266782−1474,228
−330−500−1,021−752−2,526−427
Receivables−118−549−849970−1,420−1,751
Inventories−134−203−375−514−451−752
Payables16085166−752−8142,705
Other working capital−23916837−455159−629
Tax paid−510−558−641−1,047−680−783
Capital spending7757906088987501,358
Free cash flow35631918−1,164−1,5772,087
−675−333−5284,3692−1,283
−442−520−77−3,906787−2,709
Dividends paid709313711870141
Shares bought back0000300
Shares issued000101
Net change in cash1425519198−38−547
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Consolidated, ₹ per share, years to March.Glenmark Pharmaceuticals dividend history

₹ per shareMar 2017Mar 2018Mar 2019Filed 30 MayMar 2020Filed 27 JunMar 2021Filed 31 MayMar 2022Filed 30 MayMar 2023Filed 22 MayMar 2024Filed 25 MayMar 2025Filed 12 JunMar 2026Filed 29 May
Earnings per share₹39.29₹28.49₹32.78₹27.50₹34.38₹33.37₹10.53−₹53.22₹37.11₹48.26
Diluted earnings per share₹39.28₹28.49₹32.78₹27.50₹34.38₹33.37₹10.53−₹53.22₹37.10₹48.24
Dividend per share₹2.00₹2.00₹2.00₹2.50₹2.50₹2.50₹2.50₹2.50₹2.50₹5.00
Book value per share––₹198.65₹215.14₹250.37₹322.03₹335.75₹278.11₹313.60₹372.51
Dividend payout5.1%7.0%6.1%9.1%7.3%7.5%––6.7%10.4%
Shareholder yield––––0.5%0.7%1.0%0.4%0.2%0.2%
Market cap at the year end (₹ crore)24,04414,85118,2625,80813,11212,47213,11227,04443,48760,157
RatioMar 2017Mar 2018Mar 2019Filed 30 MayMar 2020Filed 27 JunMar 2021Filed 31 MayMar 2022Filed 30 MayMar 2023Filed 22 MayMar 2024Filed 25 MayMar 2025Filed 12 JunMar 2026Filed 29 May
Revenue growth21.5%−0.9%8.4%7.9%2.8%12.4%5.6%–12.8%27.5%
Operating profit growth42.0%−20.7%−1.8%7.1%22.7%11.3%−1.8%–96.7%94.5%
Net profit growth54.0%−27.5%15.1%−16.1%25.0%2.4%−62.0%––30.1%
Earnings per share growth53.2%−27.5%15.1%−16.1%25.0%−2.9%−68.4%––30.0%
––16.5%13.3%14.8%11.7%–−17.3%12.5%14.1%
–––−3.2 pts1.5 pts−3.1 pts––29.9 pts1.5 pts
From the net margin–––−3.7 pts2.9 pts−2.0 pts–––0.3 pts
From asset turnover–––0.3 pts−0.8 pts0.5 pts–––1.0 pts
From borrowing–––0.1 pts−0.6 pts−1.6 pts–––0.3 pts
Return on capital employed––13.3%12.1%14.3%14.0%11.8%6.9%16.9%38.0%
Cash conversion––––116.6%111.6%165.7%–−79.0%252.9%
Interest cover7.54.63.83.44.66.24.81.29.019.2
Debt to equity––0.690.740.620.390.440.130.250.00
Receivable days––818386921155792107
Inventory days––244211225208240208254264
Payable days––241210221190192210216288
Cash conversion cycle, days––8584901101625612983
Working capital days––76698497108299181
Asset turnover––0.740.760.720.750.710.700.880.94
Assets per rupee of net worth––2.372.402.312.021.961.951.821.86
Sales per rupee of plant––4.703.573.703.333.333.794.014.37
Capital spending to depreciation––––1.751.620.991.541.542.37
Plant being built, % of plant in use––58.8%36.6%41.2%25.0%28.6%13.4%16.3%11.0%
Revenue growth and operating profit growth are left blank for the year to Mar 2024: between the two periods the company restated its earlier figures and the company began reporting a business as discontinued, so the two are on different bases and the change is not worked out. From the net margin, from asset turnover and from borrowing are left blank for the year to Mar 2025: the profit of this year or the year before includes a business the company has discontinued while its revenue does not, so the change in return on equity is not split into margin, turnover and borrowing. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
7.6%
Cash from operations against operating profit
75.3%
Measure10 years5 years3 years
Revenue growth, yearly rate8.4%9.2%9.3%
Profit growth, yearly rate6.6%7.0%–
Return on equity, average–5.2%3.1%
Return on capital employed, average–17.5%20.6%
Operating margin, average18.2%18.2%18.2%
Net margin, average8.1%6.7%7.9%
Asset turnover, average–0.800.84
Cash conversion cycle, days, average–10889
Interest cover, average6.48.19.8
Debt to equity, average–0.240.12

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations4,0862,3523,445
Cash from investing2,2263,088−1,283
Cash from financing−6,426−5,828−2,709
Capital spending4,4043,0061,358
Dividends paid559329141
Shares bought back30300
Shares issued for cash221
Borrowings repaid8,2244,320530

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––876268
Altman Z-scorePublished threshold 1.81––3.402.262.863.032.694.345.806.09
Beneish M-scorePublished threshold −1.78––––−2.45−2.31−2.30−3.65−1.30−2.42
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––3.391.341.54−32.8312.32−4.45
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––1.22––2.41
Receivables growth less revenue growthOur threshold 0 percentage points–––1.913.928.1326.60−45.6067.0621.04
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––−15.176.61−8.7615.66−12.8821.874.23
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––−1.552.04−0.830.440.59−1.333.00
Assets under construction, years of additionsOur threshold 2 years of additions–––0.842.870.761.35–0.790.37
Effective tax ratePublished threshold 17.16 per cent25.6628.1828.8829.2029.8331.0656.545,116.7225.1631.38
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––−7.69−17.212,246.48−23.45−8.07
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
10 Sep 2026India Ratings and Research Private Limited (opens in a new tab)Bank loan facilitiesIND AA+; IND A1+New, NewStable2,350
12 Aug 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesCrisil A1+Review, Other440
12 Aug 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesCrisil AAReview, OtherPositive450
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.